MotherToBaby

Medications and More during pregnancy and breastfeeding

Buscar

866.626.6847

High Cholesterol

Selected References:

  • Adank MC, et al. 2019. Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum?.Obstet Gynecol. 221(2): 150-e1.
  • Arias A, et al. 2022. Implications of High-Density Cholesterol Metabolism for Oocyte Biology and Female Fertility. Frontiers in cell and developmental biology, vol. 10, 941539.
  • Berge LN, et al. 1996. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet. Gynecol. Scand. 75 pp. 439–442.
  • Brizzi P, et al. 1999. Lipoprotein metabolism during normal pregnancy. Obstet Gynecol. 181 (2): 430-34.
  • Christensen S, et al. 2023. Maternal inflammatory, lipid and metabolic markers and associations with birth and breastfeeding outcomes. Frontiers in nutrition, v10, 1223753.
  • Christopher BA, et al. 2019. Evaluation and management of lipid disorders: summary. Clinical Updates in Women’s Health Care. American College of Obstetricians and Gynecologists. Obstet Gynecol. 133:609.
  • Cristodoro M, et al. 2024. Dietary Patterns and Fertility. Biology,13(2),131.
  • France M, et al. 2016. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 255:128-139.
  • Graham DF, et al. 2021. Management of familial hypercholesterolemia in pregnancy. Curr Opin Lipidol. 32(6):370-377. PMID: 34619689 DOI: 10.1097/MOL.0000000000000790
  • Goharkhay N, et al. 2008. Maternal hypercholesterolemia leads to activation of endogenous cholesterol synthesis in the offspring. Amer J Obstet Gynecol. 199(3): 273-e1.
  • Goldberg AC et al. 2011. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S1-8.
  • Gootjes D, et al. 2022. Maternal lipid profile in pregnancy and embryonic size: a population-based prospective cohort study. BMC pregnancy and childbirth; 22(1):333.
  • Jiang S et al. 2017. Maternal dyslipidemia during pregnancy may increase the risk of preterm birth: A meta-analysis. Taiwan J Obstet Gynecol. 56(1):9-15.
  • Kaneko K, et al. 2022. High Maternal Total Cholesterol Is Associated With No-Catch-up Growth in Full-Term SGA Infants: The Japan Environment and Children’s Study. Frontiers in endocrinology; vol. 13, 939366.
  • Klevmoen M, et al. 2021. Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis. 335:8-15. PMID: 34520888 DOI: 10.1016/j.atherosclerosis.2021.09.003
  • Liberis A, et al. 2021. Lipid Disorders in Pregnancy. Curr Pharm Des. 27(36):3804-3807. PMID: 33882801 DOI: 10.2174/1381612827666210421103245
  • Mauri M, et al. 2021. Dyslipemias and pregnancy, an update. Clin Investig Arterioscler. 33(1):41-52. PMID: 33309071 DOI: 10.1016/j.arteri.2020.10.002
  • Moayeri M, et al. 2017. Maternal lipid profile and the relation with spontaneous preterm delivery: a systematic review. Arch Gynecol Obstet. 295(2):313-323.
  • Mulder J, et al. 2024. Lipid metabolism during pregnancy: consequences for mother and child. Current opinion in lipidology; 35(3): 133-140.
  • Napoli C, et al. 1999. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 354(9186): 1234-41.
  • Nasioudis D, et al. 2018. Dyslipidemia in pregnancy and maternal-fetal outcome. Minerva ginecologica. 71(2):155-62.
  • Ogura et al. 2016. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis. 254:179-183.
  • Omolaoye T, et al. 2022. Statins and Male Fertility: Is There a Cause for Concern?. Toxics; 10(10):627.
  • Pugh et al. 2017. Preconception maternal lipoprotein levels in relation to fecundability. Hum Reprod.15:1-9.
  • Pushpendra A, et al. 2015. Hyper-lipidemia and male fertility: a critical review of literature. Andrology. 4(2).
  • Schisterman EF, et al. 2014. Lipid concentrations and couple fecundity: the LIFE study. J Clin Endocrinol Metab. 99(8):2786-94.
  • Schisterman EF, et al. 2014. Lipid concentrations and semen quality: the LIFE study. Andrology. 2(3):408-15.
  • Sharami SH, 2019. The relationship of hyperlipidemia with maternal and neonatal outcomes in pregnancy: A cross-sectional study. International Journal of Reproductive BioMedicine. 17(10): 739.
  • Smith CJ, et al. 2018. Maternal dyslipidemia and risk for preterm birth. PloS one. 13(12): e0209579.
  • Toleikyte I, et al. 2011. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 124(15):1606-14.
  • Varnier NA, et al. 2015. Coronary artery disease secondary to familial hypercholesterolaemia: An infrequent cause of increasingly common pregnancy co-morbidity. Obstet Med.8(3):152-4.
  • Vrijkotte TG, et al. 2012. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. The Journal of Clinical Endocrinology & Metabolism. 97(11): 3917-25.
  • Wang C, et al. 2016. The associations between early pregnancy lipid profiles and pregnancy outcomes. J Perinatol.
  • Whitfield M, et al. 2015. Posttesticular sperm maturation, infertility, and hypercholesterolemia. Asian J Androl. 17(5):742-8.
  • Wild R, et al. 2015. Dyslipidemia in pregnancy. Cardiology clinics. 33(2): 209-15.
  • Wojcik-Baszko D, et al. 2018. Role of dyslipidemia in preeclampsia—A review of lipidomic analysis of blood, placenta, syncytiotrophoblast microvesicles and umbilical cord artery from women with preeclampsia. Prostaglandins & Other Lipid Mediators. 139: 19-23.

MotherToBaby cuenta con el apoyo de la Administración de Recursos y Servicios de Salud (HRSA) del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) como parte de una adjudicación por un total de $6,000,000 con cero porcentaje financiado con fuentes no gubernamentales. Los contenidos son los del autor/es y no representan necesariamente los puntos de vista oficiales de, ni un respaldo, por HRSA, HHS o el Gobierno de los Estados Unidos.